Assessment of Quality of Life and Treatment Outcomes of Patients with Persistent Postchemotherapy Alopecia

Azael Freites-Martinez, Donald Chan, Vincent Sibaud, Jerry Shapiro, Gabriella Fabbrocini, Antonella Tosti, Juhee Cho, Shari Goldfarb, Shanu Modi, Devika Gajria, Larry Norton, Ralf Paus, Tessa Cigler, Mario E. Lacouture

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Importance: Persistent alopecia occurs in a subset of patients undergoing chemotherapy, yet the quality of life (QOL) of these patients and their response to therapy have not been described in a large patient cohort. Objective: To characterize the clinical presentation of patients with persistent chemotherapy-induced alopecia (pCIA) or endocrine therapy-induced alopecia after chemotherapy (EIAC) and their QOL and treatment outcomes. Design, Setting, and Participants: A retrospective multicenter cohort of 192 women with cancer treated with cytotoxic agents who received a clinical diagnosis of persistent alopecia (98 with pCIA and 94 with EIAC) between January 1, 2009, and July 31, 2017, was analyzed. All patients were from the dermatology service in 2 comprehensive cancer centers and 1 tertiary-care hospital. Data on demographics, chemotherapy regimens, severity, clinical patterns, and response to hair-growth promoting agents were assessed. Data from the Hairdex questionnaire were used to assess the QOL of patients with alopecia. Main Outcomes and Measures: The clinical presentation, response to dermatologic therapy, and QOL of patients with pCIA were assessed and compared with those of patients with EIAC. Results: A total of 98 women with pCIA (median age, 56.5 years [range, 18-83 years]) and 94 women with EIAC (median age, 56 years [range, 29-84 years]) were included. The most common agents associated with pCIA were taxanes for 80 patients (82%); the most common agents associated with EIAC were aromatase inhibitors for 58 patients (62%). Diffuse alopecia was predominant in patients with pCIA compared with patients with EIAC (31 of 75 [41%] vs 23 of 92 [25%]; P =.04), with greater severity (Common Terminology Criteria for Adverse Events, version 4.0, grade 2) among patients with pCIA (29 of 75 [39%] vs 12 of 92 [13%]; P <.001). A negative emotional effect was reported by both groups. After treatment with topical minoxidil or spironolactone, moderate to significant improvement was observed for 36 of 54 patients with pCIA (67%) and for 32 of 42 patients with EIAC (76%). Conclusions and Relevance: Persistent chemotherapy-induced alopecia is frequently more severe and diffuse when compared with EIAC, and both groups of patients experienced a negative effect. A modest benefit was observed with dermatologic therapy. Additional studies are warranted to develop effective strategies for prevention and effective therapy for pCIA and EIAC..

Original languageEnglish (US)
Pages (from-to)724-728
Number of pages5
JournalJAMA dermatology
Volume155
Issue number6
DOIs
StatePublished - Jun 2019

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Assessment of Quality of Life and Treatment Outcomes of Patients with Persistent Postchemotherapy Alopecia'. Together they form a unique fingerprint.

  • Cite this

    Freites-Martinez, A., Chan, D., Sibaud, V., Shapiro, J., Fabbrocini, G., Tosti, A., Cho, J., Goldfarb, S., Modi, S., Gajria, D., Norton, L., Paus, R., Cigler, T., & Lacouture, M. E. (2019). Assessment of Quality of Life and Treatment Outcomes of Patients with Persistent Postchemotherapy Alopecia. JAMA dermatology, 155(6), 724-728. https://doi.org/10.1001/jamadermatol.2018.5071